What was the major announcement regarding Sigma Healthcare (ASX:SIG)?

Sigma Healthcare (ASX:SIG) has officially entered the United Kingdom market by acquiring a 75% majority stake in Greenlight Healthcare, a London-based pharmacy chain with 22 stores.

How does the UK acquisition fit into the Sigma Healthcare (ASX:SIG) long-term strategy?

International expansion is a core pillar of the Sigma Healthcare (ASX:SIG) strategy, as management aims to diversify revenue away from the mature Australian market. CEO Vikesh Ramsunder has indicated that the company's global operations could eventually outsize its domestic footprint.

What are the financial terms and risks of the Greenlight Healthcare deal?

While specific financial terms were not disclosed, Greenlight Healthcare reported a pre-tax loss of £1.1 million ($2.1 million) in the 12 months to June 2024. This represents a "turnaround" play for Sigma, as they are acquiring an underperforming business in a difficult UK trading environment.

What is driving the 16.7% sales growth in Sigma’s Australian network?

The double-digit sales growth in Sigma's domestic network is largely attributed to the massive surge in demand for GLP-1 weight-loss medications, such as Ozempic and Wegovy. While these products drive significant foot traffic and top-line revenue, retail investors should monitor whether these are high-margin sales or simply volume-based drivers.

How will the Greenlight Healthcare partnership operate on the ground?

Sigma Healthcare (ASX:SIG) will acquire 75% of the stores, while the remaining 25% remains with the original British employee-owners. Greenlight will continue to provide the essential dispensary and back-office support, while licensing the Chemist Warehouse brand for the storefronts.

What are the main bull and bear points for Sigma Healthcare (ASX:SIG) after this news?

The bull case focuses on Sigma's proven ability to scale the Chemist Warehouse model internationally and the tailwinds from the GLP-1 drug boom. Conversely, the bear case highlights the 10% share price drop over the last year and the "UK graveyard" risk, where other Australian retailers like Bunnings famously failed. Investors must weigh the potential for a massive new addressable market against the integration risks of a loss-making UK chain.

Chemist Warehouse to expand into United Kingdom

Written by Brie CarterPublished May. 4 2026Last Updated May. 4 2026

Australian retail giant Sigma Healthcare (ASX:SIG) announced its foray into the United Kingdom, securing a majority stake in the London-based Greenlight Healthcare chain.

The strategic acquisition marks a milestone for the Chemist Warehouse brand, which is set to debut in the British market following a 75% buy-in of the 22-store network.

Under the new agreement, Greenlight Healthcare—formerly a purely employee-owned entity—will license the iconic Chemist Warehouse branding while maintaining responsibility for dispensary services and back-office operations.

Sigma CEO Vikesh Ramsunder, who is slated to detail the expansion at the Macquarie Australia conference on May 5, emphasised that international growth remains a pillar of the company’s long-term strategy.

Ramsunder previously suggested that the brand's global footprint could eventually surpass its domestic presence.

The move comes as Sigma reports robust performance across its existing international territories, including New Zealand, Ireland, and Dubai, where sales have surged by nearly 25%.

Domestically, the group has seen a 16.7% rise in sales, bolstered significantly by the soaring demand for GLP-1 medications such as Ozempic.

While Greenlight reported a pre-tax loss of £1.1 million in its latest accounts, Sigma intends to revitalise the network, starting with the rebranding of five initial pilot stores.